Voyager Therapeutics (VYGR) to Release Earnings on Monday

Voyager Therapeutics (NASDAQ:VYGR) is set to announce its earnings results after the market closes on Monday, May 13th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of ($0.59) by $1.84. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. The firm had revenue of $90.06 million during the quarter, compared to analyst estimates of $4.95 million. On average, analysts expect Voyager Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Voyager Therapeutics Stock Performance

Shares of NASDAQ VYGR traded down $0.04 during trading on Tuesday, reaching $8.90. The stock had a trading volume of 132,039 shares, compared to its average volume of 865,471. The stock has a market cap of $484.07 million, a PE ratio of 2.91 and a beta of 0.98. The firm’s 50 day moving average price is $8.86 and its two-hundred day moving average price is $8.01. Voyager Therapeutics has a one year low of $6.06 and a one year high of $14.34.

Analyst Upgrades and Downgrades

VYGR has been the topic of several research reports. Guggenheim assumed coverage on shares of Voyager Therapeutics in a research note on Tuesday, March 26th. They set a “buy” rating and a $22.00 price objective on the stock. Citigroup assumed coverage on shares of Voyager Therapeutics in a report on Thursday, March 7th. They set a “buy” rating and a $16.00 price target for the company. StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th. Finally, HC Wainwright started coverage on shares of Voyager Therapeutics in a research note on Tuesday, March 19th. They set a “buy” rating and a $30.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $19.33.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.